Compounds > deferoxamine

deferoxamine and amifostine anhydrous

deferoxamine has been researched along with amifostine anhydrous in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (14.29)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (71.43)	24.3611
2020's	1 (14.29)	2.80

Authors

Authors	Studies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Schacht, J; Song, BB	1
Harsini, S; Javan-Farazmand, N; Kajbafzadeh, AM; Sabetkish, N; Sabetkish, S; Tavangar, SM	1
Buchman, SR; Deshpande, SS; Donneys, A; Figueredo, C; Kozloff, KM; Nelson, NS; Perosky, JE; Polyatskaya, Y; Ratliff, HC; Rodriguez, JJ; Vasseli, CA	1
Buchman, SR; Carey, EG; Donneys, A; Lynn, JV; Mazzoli, AC; Nelson, NS; Polyatskaya, Y; Urlaub, KM	1
Allen, RJ; Chu, JJ; Kim, LN; Mehrara, BJ; Nelson, JA; Rubenstein, RN	1

Reviews

2 review(s) available for deferoxamine and amifostine anhydrous

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Noninvasive Systemic Modalities for Prevention of Head and Neck Radiation-Associated Soft Tissue Injury: A Narrative Review. Journal of reconstructive microsurgery, 2022, Volume: 38, Issue:8 Topics: Amifostine; Deferoxamine; Fibroblast Growth Factor 7; Humans; Melatonin; Pravastatin; Soft Tissue Injuries; Transforming Growth Factors	2022

Other Studies

5 other study(ies) available for deferoxamine and amifostine anhydrous

Article	Year
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo. Hearing research, 1996, Volume: 94, Issue:1-2 Topics: Administration, Oral; Allopurinol; Amifostine; Analysis of Variance; Animals; Anti-Bacterial Agents; Antimetabolites; Antioxidants; Auditory Threshold; Benzoates; Deferoxamine; Dimethyl Sulfoxide; Free Radical Scavengers; Gentamicins; Guinea Pigs; Hydroxybenzoates; Injections, Intraperitoneal; Injections, Subcutaneous; Iron; Iron Chelating Agents; Male; Mannitol; Pregnatrienes	1996
The ameliorative effect of various antioxidants on Adriamycin-induced fetal renal abnormalities. Journal of pediatric urology, 2013, Volume: 9, Issue:6 Pt B Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antioxidants; Deferoxamine; Disease Models, Animal; Doxorubicin; Female; Fetal Diseases; Hydronephrosis; Kidney; Pregnancy; Prenatal Exposure Delayed Effects; Radiation-Protective Agents; Random Allocation; Rats; Rats, Sprague-Dawley; Siderophores	2013
Prevention of radiation-induced bone pathology through combined pharmacologic cytoprotection and angiogenic stimulation. Bone, 2016, Volume: 84 Topics: Amifostine; Angiography; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases; Cytoprotection; Deferoxamine; Male; Neovascularization, Physiologic; Radiation Injuries; Rats, Sprague-Dawley	2016
Histologic Improvements in Irradiated Bone Through Pharmaceutical Intervention in Mandibular Distraction Osteogenesis. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2018, Volume: 76, Issue:12 Topics: Amifostine; Animals; Deferoxamine; Drug Therapy, Combination; Male; Mandible; Osteogenesis, Distraction; Radiation Injuries; Radiation-Protective Agents; Random Allocation; Rats; Rats, Sprague-Dawley; Treatment Outcome	2018